| ID | stock | number | price | Field1 | plan | current price | share amount | current lost price | net loss | fill amount | filled price | fill total | grand total | grand share | grand avg | GAP |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7 | VERB | $100.00 | $0.78 | $77.67 | $0.20 | $100.00 | $20.00 | ($57.67) | $0.00 | $0.00 | $0.00 | $77.67 | $100.00 | $0.78 |
Blog Archive
News
Stock Forecasts
Tuesday, January 24, 2023
VERB
Tuesday, January 17, 2023
CRDL reverse buy back
| ID | stock | number | price | Field1 | plan | current price | share amount | current lost price | net loss | fill amount | filled price | fill total | grand total | grand share | grand avg | GAP |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5 | CRDL | $92.00 | $2.72 | $250.24 | $0.67 | $92.00 | $61.64 | ($188.60) | $0.00 | $0.00 | $0.00 | $250.24 | $92.00 | $2.72 |
| ID | stock | number | price | Field1 | plan | current price | share amount | current lost price | net loss | fill amount | filled price | fill total | grand total | grand share | grand avg | GAP |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 | CRDL | $101.00 | $0.77 | $77.27 | $0.78 | $101.00 | $78.29 | $1.02 | $0.00 | $0.00 | $0.00 | $77.27 | $101.00 | $0.77 |
| ID | stock | number | price | Field1 | plan | current price | share amount | current lost price | net loss | fill amount | filled price | fill total | grand total | grand share | grand avg | GAP |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 | CRDL | $101.00 | $0.77 | $77.27 | $0.77 | $100.00 | $76.50 | ($0.77) | $0.00 | $0.00 | $0.00 | $77.27 | $101.00 | $0.77 |
Cardiol Therapeutics Inc. (NASDAQ: CRDL) is a clinical-stage life sciences company specializing in anti-inflammatory and anti-fibrotic therapies for heart diseases.
Financial Overview:
Revenue: For the fiscal year ending December 31, 2023, Cardiol Therapeutics reported minimal revenue, consistent with its status as a clinical-stage company.
Net Loss: The company recorded a net loss of approximately $20.84 million for the same period, reflecting ongoing research and development expenditures.
Cash Position: As of December 31, 2023, the company held cash and short-term investments totaling approximately $34.93 million, providing a financial runway for its clinical programs.
Analyst Ratings and Price Targets:
Consensus Rating: Cardiol Therapeutics has received a consensus rating of "Buy" from multiple analysts, indicating optimism about the company's prospects.
Price Targets: The average twelve-month price target is $8.75, with estimates ranging from $7.89 to $10.00, suggesting a significant potential upside from the current share price.
Recent Analyst Activity: On December 18, 2024, HC Wainwright reiterated a "Buy" rating with a $9.00 price target, reflecting confidence in the company's strategic direction.
Recent Developments:
Clinical Trials:
The company has completed patient enrollment in its Phase II
MAvERIC-Pilot study investigating CardiolRx™ for recurrent pericarditis, with topline results expected in Q2 2024.
Regulatory Designations: CardiolRx™ has been granted Orphan Drug Designation by the U.S. FDA for the treatment of pericarditis, potentially expediting its development and approval process.
Considerations for Investors:
While Cardiol Therapeutics shows promise with its innovative therapies and favorable analyst outlook, potential investors should be mindful of the inherent risks associated with clinical-stage biotech companies, including regulatory hurdles, clinical trial outcomes, and market competition.
It's advisable to conduct thorough due diligence and consider these factors when evaluating investment opportunities in the biotech sector.
CALA REVERSE BUY BACK
TODAY SELL OFF CALA AND BUY BACK
NET LOSS 22 $ TO GET BACK CALA
RIGHT NOW GAIN 1.29
TO WAIT TILL 22 $ TRADE IN AND OUT
MULN reverse net loss 40$ buy 600 share
NET LOSS 303 $ GAIN 80 $ TO GET 223
NET LOSS 40 $ GAIN 0 $ TO GET 40
TO GET TOTAL 263 $
| ID | stock | number | price | TOTAL PRICE | plan | current price | NUMBER OF SHARE | current lost price | net loss | fill amount | filled price | fill total | grand total | grand share | grand avg | GAP |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 | MULN | $520.00 | $0.22 | $115.28 | $0.22 | $520.00 | $112.22 | ($3.07) | $520.00 | $0.22 | $112.27 | $227.55 | $1,040.00 | $0.22 | ||
| 14 | MULN | $520.00 | $0.80 | $416.00 | $0.22 | $520.00 | $112.22 | ($303.78) | $0.00 | $0.00 | $0.00 | $416.00 | $520.00 | $0.80 | ||
| 23 | MULN | $4,000.00 | $0.24 | $960.00 | $0.30 | $4,000.00 | $1,200.00 | $240.00 | $0.00 | $0.00 | $0.00 | $960.00 | $4,000.00 | $0.24 |
Tuesday, January 10, 2023
MULN FILL THE SHORT
MULN SELL OFF 4 JAN 2023 1100 SHARE 0.32 TOTAL 352 $
| ID | stock | number | price | TOTAL PRICE | plan | current price | NUMBER OF SHARE | current lost price | net loss | fill amount | filled price | fill total | grand total | grand share | grand avg | GAP |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 | MULN | $520.00 | $0.22 | $115.28 | $0.22 | $520.00 | $112.22 | ($3.07) | $520.00 | $0.22 | $112.27 | $227.55 | $1,040.00 | $0.22 | ||
| 14 | MULN | $520.00 | $0.80 | $416.00 | $0.22 | $520.00 | $112.22 | ($303.78) | $0.00 | $0.00 | $0.00 | $416.00 | $520.00 | $0.80 | ||
| 23 | MULN | $4,000.00 | $0.24 | $960.00 | $0.30 | $4,000.00 | $1,200.00 | $240.00 | $0.00 | $0.00 | $0.00 | $960.00 | $4,000.00 | $0.24 |
Friday, December 30, 2022
New Fed research flags rising risk of U.S. recession
Just over half of the 50 U.S. states are exhibiting signs of slowing economic activity, breaching a key threshold that often signals a recession is in the offing, new research from the St. Louis Federal Reserve Bank report said.
That report, released Wednesday, followed another report from the San Francisco Fed from earlier in the week that also delved into the rising prospect that the U.S. economy may fall into recession at some point in coming months.
The St. Louis Fed said in its report that if 26 states have falling activity within their borders, that offers "reasonable confidence" that the nation as a whole will fall into a recession.
Right now, the bank said that as measured by Philadelphia Fed data tracking the performance of individual states, 27 had declining activity in October. That's enough to point to a looming downturn while standing short of the numbers that have been seen ahead of some other recessions. The authors noted that 35 states suffered declines ahead of the short and sharp recession seen in the spring of 2020, for example.
Meanwhile, a San Francisco Fed report, released Tuesday, observed that changes in the unemployment rate can also signal a downturn is on the way, in a signal that offers more near-term predictive value than the closely-watched bond market yield curve.
The paper's authors said that the unemployment rate bottoms out and begins to move higher ahead of recession in a highly reliable pattern. When this shift occurs the unemployment rate is signaling the onset of recession in about eight months, the paper said.
The paper acknowledged its findings are akin to those of the Sahm Rule, named for former Fed economist Claudia Sahm, who pioneered work linking a rise in the jobless rate to economic downturns. The San Francisco Fed research, written by bank economist Thomas Mertens, said its innovation is to make the jobless rate change a forward-looking indicator.
Unlike the St. Louis Fed state data that is tipping toward a recession projection, the U.S. jobless rate has thus far remained fairly stable, and after bottoming at 3.5% in September, it held at 3.7% in both October and November.
The San Francisco Fed paper noted that the Fed, as of its December forecasts, sees the unemployment rate rising next year amid its campaign of aggressive rate hikes aimed at cooling high levels of inflation. In 2023, the Fed sees the jobless rate jumping up to 4.6% in a year where it sees only modest levels of overall growth.
If the Fed's forecast comes to pass, "such an increase would trigger a recession prediction based on the unemployment rate," the paper said. "Under this view, low unemployment can lead to a heightened probability of recession when the unemployment rate is expected to rise."
Tim Duy, chief economist with SGH Macro Advisors, said he believes that to achieve what the Fed wants on the inflation front, the economy would likely "lose roughly two million jobs, which would be a recession like 1991 or 2001."
Anxiety over the prospect of the economy falling into recession has been driven by the Fed's forceful actions on inflation. Many critics contend that the central bank is focusing too much on inflation and not enough on keeping Americans employed. Central bank officials have countered that without a return to price stability, the economy will struggle to meet its full potential.
What's more, in the press conference following the most recent Federal Open Market Committee meeting earlier this month, central bank leader Jerome Powell said that he didn't view the current Fed outlook as a recession prediction given the expectation growth will remain positive. But he added much remains uncertain.
"I don't think anyone knows whether we're going to have a recession or not and, if we do, whether it's going to be a deep one or not. It's just, it's not knowable," Powell said.
(Reporting by Michael S. Derby; Editing by Dan Burns and Aurora Ellis)
UAVS as of 12/30 /2022
My stock market value
$32.00
| Today‘s return | +$0.42 (+1.33%) | |
| Total return | -$219.41 (-87.27%) |
Shares 100
| Portfolio diversity | 0.86% |
AgEagle
Aerial Systems, Inc. engages in the design and manufacture of drones
for commercial use. The firm also enables the capturing, imaging,
editing, and analyzing of images and data captured by drones and intends
on using commercial drones to be used for delivery services of goods.
It offers contract manufacturing, drone solutions, and agriculture
solutions. The company was founded on March 31, 1999 and is
headquartered in Wichita, KS (. The listed name for UAVS is AgEagle Aerial
Systems, Inc. City Hall Wichita, Kansas
![]()
AgEagle Aerial Systems (UAVS) has 1 split in our AgEagle Aerial Systems stock split history
database. The split for UAVS took place on March 27, 2018. This was a
1 for 25 reverse split, meaning for each 25 shares of UAVS owned
pre-split, the shareholder now owned 1 share. For example, a 1000 share
position pre-split, became a 40 share position following the split.
When a company such as AgEagle Aerial Systems conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the AgEagle Aerial Systems stock split history from start to finish, an original position size of 1000 shares would have turned into 40 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into AgEagle Aerial Systems shares, starting with a $10,000 purchase of UAVS, presented on a split-history-adjusted basis factoring in the complete AgEagle Aerial Systems stock split history.
Start date: 01/02/2013
End date: 12/29/2022
Start price/share: $12.50
End price/share: $0.32
Dividends collected/share: $0.00
Total return: -97.44%
Average Annual Total Return: -30.70%
Starting investment: $10,000.00
Ending investment: $255.98
Years: 9.99
IDEX reverse split compare 1 week 1 month 3 month 1 year to invest long term to check financial
11.81M
What this means: InvestorsObserver gives Ideanomics Inc (IDEX) an overall rank of 34, which is below average. Ideanomics Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 34 means that 66% of stocks appear more favorable to our system.
Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.
- Ideanomics (IDEX): Forward revenue estimates point to a robust future ahead for the business
Ideanomics Inc (IDEX) Analyst Forecast
IDEX Price, Volume, Earnings, and Dividend Date
- Last Price$0.17
- Previous Close$0.17
- Change$0.00
- Open$0.19
- Volume22,413,560
- Avg. Volume (100-day)9,949,718
- Market Cap101,503,787
- Days Range0.1722 - 0.1853
- 52-week Range0.14 - 1.15
- Dividend Yield—
- Ex. Dividend Date—
- P-E—
- EPS—
- Earnings Date02/07/23
- SectorTechnology
- IndustrySoftware - Application
- Avg. Analyst Rec.Premium
- Beta1.904
- PEG Ratio


































